PCM
AKBA icon

Polymer Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Polymer Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.7K Sell
21,394
-51,423
-71% -$70.7K ﹤0.01% 802
2025
Q4 		$117K Buy
72,817
+54,585
+299% +$114K 0.01% 722
2025
Q3 		$49.8K Buy
18,232
+6,034
+49% +$20.1K 0.01% 743
2025
Q2 		$44.4K Buy
+12,198
New +$33.5K 0.01% 594

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Polymer Capital Management's AKBA Position: Q1 2026 in Review

Polymer Capital Management reduced its Akebia Therapeutics (AKBA) stake by 71% in Q1 2026, selling an estimated $70.7K and leaving 21,394 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #802.

Polymer Capital Management first reported a position in AKBA in Q2 2025 and has held it in 4 quarters since. The position peaked at $117K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Polymer Capital Management held 21,394 shares of Akebia Therapeutics worth $29.7K as of Q1 2026.
  • Polymer Capital Management sold 51,423 Akebia Therapeutics shares in Q1 2026, an estimated $70.7K.
  • Akebia Therapeutics made up ﹤0.01% of Polymer Capital Management's portfolio in Q1 2026, its #802 holding.
  • Polymer Capital Management first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Polymer Capital Management's Akebia Therapeutics position peaked at $117K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.